PDS Biotechnology 過去の業績
過去 基準チェック /06
PDS Biotechnologyの収益は年平均-13.7%で減少しているが、Biotechs業界はgrowingで33.8%年平均の収益となった。
主要情報
-13.73%
収益成長率
-2.77%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | n/a |
| 株主資本利益率 | -360.53% |
| ネット・マージン | n/a |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
新しいナラティブ • Apr 02
Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 19
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 05
HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 13
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
PDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.Seeking Alpha • Aug 24
PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.Seeking Alpha • Aug 04
PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.分析記事 • Jul 08
PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • May 27
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients. Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established. PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.Seeking Alpha • Feb 22
PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level.収支内訳
収支内訳
PDS Biotechnology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -33 | 12 | 17 |
| 31 Dec 25 | 0 | -34 | 13 | 19 |
| 30 Sep 25 | 0 | -35 | 13 | 19 |
| 30 Jun 25 | 0 | -37 | 13 | 21 |
| 31 Mar 25 | 0 | -35 | 14 | 22 |
| 31 Dec 24 | 0 | -38 | 14 | 23 |
| 30 Sep 24 | 0 | -41 | 14 | 26 |
| 30 Jun 24 | 0 | -41 | 15 | 25 |
| 31 Mar 24 | 0 | -44 | 15 | 29 |
| 31 Dec 23 | 0 | -43 | 15 | 28 |
| 30 Sep 23 | 0 | -51 | 15 | 36 |
| 30 Jun 23 | 0 | -48 | 14 | 34 |
| 31 Mar 23 | 0 | -42 | 13 | 30 |
| 31 Dec 22 | 0 | -41 | 12 | 29 |
| 30 Sep 22 | 0 | -28 | 13 | 17 |
| 30 Jun 22 | 0 | -28 | 13 | 16 |
| 31 Mar 22 | 0 | -22 | 12 | 15 |
| 31 Dec 21 | 0 | -17 | 10 | 11 |
| 30 Sep 21 | 0 | -15 | 9 | 10 |
| 30 Jun 21 | 0 | -12 | 7 | 9 |
| 31 Mar 21 | 0 | -14 | 7 | 7 |
| 31 Dec 20 | 0 | -15 | 7 | 8 |
| 30 Sep 20 | 0 | -15 | 7 | 7 |
| 30 Jun 20 | 0 | -17 | 8 | 7 |
| 31 Mar 20 | 0 | -18 | 9 | 7 |
| 31 Dec 19 | 0 | -7 | 11 | 6 |
| 30 Sep 19 | 0 | -5 | 11 | 5 |
| 30 Jun 19 | 0 | 0 | 8 | 3 |
| 31 Mar 19 | 0 | 4 | 6 | 2 |
| 31 Dec 18 | 0 | -4 | 3 | 1 |
| 30 Sep 18 | 0 | -2 | 2 | 1 |
| 31 Dec 17 | 0 | -3 | 1 | 2 |
質の高い収益: PDSBは現在利益が出ていません。
利益率の向上: PDSBは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: PDSBは利益が出ておらず、過去 5 年間で損失は年間13.7%の割合で増加しています。
成長の加速: PDSBの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: PDSBは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。
株主資本利益率
高いROE: PDSBは現在利益が出ていないため、自己資本利益率 ( -360.53% ) はマイナスです。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/24 15:30 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
PDS Biotechnology Corporation 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |